Twitxy
Saved
@PharmaReview's profile picture
View on X

European Pharmaceutical Review

@PharmaReview

The leading FREE journal for up-to-the-minute information and news on all aspects of drug analysis, formulation, delivery, manufacturing and regulation.
United Kingdom europeanpharmaceuticalreview.com Joined April 2010
1.5K Following 15K Followers 23K Posts

Latest posts 5

European Pharmaceutical Review @PharmaReview
According to analysis by @moderna_tx, 20 percent of participants in UK industry-sponsored clinical research were enrolled in a Moderna trial in 2023/2024. europeanpharmaceuticalreview.com/news/246638/mo…
www.europeanpharmaceuticalreview.com Moderna reports record for UK clinical trials in 2023/24 The announcement follows the completed construction of Moderna's MITC and progress in its long-term partnership with the UK government.
European Pharmaceutical Review @PharmaReview
“Excitingly, advances in gene editing are happening very rapidly... it seems likely that cheaper, safer and more effective forms of gene editing will emerge for sickle cell disease over the coming years,” commented Professor Rees of King’s College London.
europeanpharmaceuticalreview.com/news/245870/ni…
www.europeanpharmaceuticalreview.com NICE recommends gene therapy for severe sickle cell disease The committee's approval of the one-time gene therapy means the healthcare inequalities for patients with this genetic blood disorder can begin to be re-addressed.
European Pharmaceutical Review @PharmaReview
"This year’s figures demonstrate that biotech is a vibrant growth sector of the UK economy with an exceptional ability to attract global investment," says @BIA_UK's CEO. europeanpharmaceuticalreview.com/news/245461/uk…
www.europeanpharmaceuticalreview.com UK biotech on “positive trajectory”, says BIA Cutting-edge science and large international investment are driving growth in the UK's biotech sector, the organisation's new report reveals.
European Pharmaceutical Review @PharmaReview
@US_FDA 's approval offers patients opportunity to "experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral antidepressants,” explained Global Therapeutic Area Head, Neuroscience, @JNJInnovation europeanpharmaceuticalreview.com/news/245004/fd…
www.europeanpharmaceuticalreview.com FDA approves innovative monotherapy for treatment-resistant depression J&J's standalone small molecule drug was approved based on evidence of improvement of depressive symptoms without the need for patients to take a daily oral antidepressant.
European Pharmaceutical Review @PharmaReview
"With nearly two-thirds of all major #pharma company revenues set to come from dealmaking in the next five years, deals will remain at the centre of #lifesciences strategy," says @EYnews Global Life Sciences Deals Leader. europeanpharmaceuticalreview.com/article/245077…
www.europeanpharmaceuticalreview.com M&A outlook for pharma in 2025 For a strong 2025, dealmaking should be central to the life sciences strategy, says EY's annual M&A report.